Children, Perennial Allergic Rhinitis (PAR), l-t Growth

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00641212
Recruitment Status : Completed
First Posted : March 24, 2008
Last Update Posted : March 25, 2009
Information provided by:

March 18, 2008
March 24, 2008
March 25, 2009
January 2000
April 2003   (Final data collection date for primary outcome measure)
Change in height over a 12 month period [ Time Frame: 3 monthly ]
Same as current
Complete list of historical versions of study NCT00641212 on Archive Site
  • Change in growth velocity over a 12 month period. [ Time Frame: 3 monthly ]
  • Other safety - assessed by adverse event query [ Time Frame: 3 monthly ]
Same as current
Not Provided
Not Provided
Children, Perennial Allergic Rhinitis (PAR), l-t Growth
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Long-Term Treatment With Rhinocort Aqua (Budesonide) Nasal Spray in Children With Perennial Allergic Rhinitis.
The purpose of this study is to compare the effect of Rhinocort nasal spray with placebo on growth in children with perennial allergic rhinitis over 12 months.
Not Provided
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Perennial Allergic Rhinitis
  • Drug: Budesonide
    Other Name: Rhinocort AQUA
  • Drug: Placebo
  • Experimental: 1
    Intervention: Drug: Budesonide
  • Placebo Comparator: 2
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
April 2003
April 2003   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • In the opinion of the investigator, is a candidate for treatment with nasal steroids based on a history of either a) inadequate control of symptoms with antihistamines, decongestants and/or immunotherapy, or b) prior successful treatment with nasal steroids.
  • A documented history of at least one year of perennial allergic rhinitis.
  • A positive response to a skin prick test for perennial allergens that must be present in the subject's environment.
  • Height and weight within normal limits.

Exclusion Criteria:

  • Any disease which may affect growth
  • Sexual development later than Tanner stage I.
  • Nasal candidiasis, rhinitis medicamentosa, acute or chronic sinusitis, influenza, upper respiratory tract infection or structural abnormalities of the nose (e.g., septal deviation, nasal polyps) symptomatic enough to cause significant nasal obstruction as judged by the investigator.
Sexes Eligible for Study: All
4 Years to 10 Years   (Child)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Study Director: Bertil Andersson AstraZeneca
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP